

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention
 1600 Clifton Road, NE, Tom Harkin Global Communications Center (Building 19), Kent "Oz" Nelson Auditorium
 Atlanta, Georgia 30333
June 20-21, 2012

AGENDA ITEM	PURPOSE	PRESIDER / PRESENTER(S)
<u>Wednesday, June 20, 2012</u>		
8:00 AM - Welcome and Introductions		Dr. Carol Baker (ACIP Chair) Dr. Larry Pickering (ACIP Executive Secretary; CDC)
8:30 AM - Pneumococcal Vaccines		
Introduction	Information & Discussion	Dr. Nancy Bennett (ACIP, WG Chair)
Impact of PCV13 use in children		Dr. Matthew Moore (CDC/NCIRD)
PPSV23 for adults with immunocompromising conditions: background, review of data, and GRADE		Ms. Tamara Pilishvili (CDC/NCIRD)
PCV13 for adults with immunocompromising conditions: background, review of data, and GRADE		Dr. Kathleen Dooling (CDC/NCIRD)
Cost-effectiveness of PCV13 for adults with immunocompromising conditions		Dr. Charles Stoecker (CDC/NCIRD)
Recommendations for PCV13 use among immunocompromised adults	<u>Vote</u>	Ms. Tamara Pilishvili (CDC/NCIRD)
10:15 AM - Break		
10:45 AM - Influenza		
Introduction	Information & Discussion	Dr. Wendy Keitel (ACIP, WG Chair)
Influenza activity/surveillance update		Dr. Lyn Finelli (CDC/NCIRD)
Vaccine effectiveness		Dr. David Shay (CDC/NCIRD)
Vaccine safety update		Dr. Tom Shimabukuro (CDC/NCEZID)
Proposed recommendations	<u>Vote & VFC Vote</u>	Dr. Lisa Grohskopf (CDC/NCIRD)
12:00 PM - Lunch		
1:15 PM - Hepatitis B Protection for Healthcare Personnel (HCP)		
Introduction	Information & Discussion	Dr. Mark Sawyer (ACIP, WG Chair)
Overview of hepatitis B protection among HCP		Dr. Sarah Schillie (CDC/NCHHSTP)
Risk of exposure and antibody levels over time		Ms. Meredith Reilly (CDC/NCHHSTP)
Hepatitis B protection among HCP: cost-effectiveness considerations		Dr. Tom Hoerger (Senior Fellow, RTI International)
Future considerations		Dr. Sarah Schillie (CDC/NCHHSTP)
3:15 PM - Break		
3:45 PM - Pertussis Vaccines		
Update: ACIP Pertussis Vaccines Work Group	Information	Dr. Mark Sawyer (ACIP, WG Chair) Dr. Jeffrey Duchin (ACIP; Chief Communicable Disease Epidemiology & Immunization Section, Public Health-Seattle & King County)
Update: pertussis outbreak in Washington State		
4:10 PM - Meningococcal Vaccines		
Update: Meningococcal Vaccines Work Group	Information	Dr. Cody Meissner (ACIP, WG Chair)
4:25 PM - Development of Evidence-Based Recommendations Using GRADE		
Development of ACIP/CDC vaccine recommendations using GRADE	Information & Discussion	Dr. Jonathan Temte (ACIP)
Strategic Advisory Group of Experts on Immunization (SAGE) approach to updating WHO Vaccine Position Papers		Professor David Durrheim, University of Newcastle, Australia; SAGE Member
Update on GRADE		Dr. Faruque Ahmed (CDC/NCIRD)
5:10 PM - Vaccine Supply		
	Information	Dr. Jeanne Santoli (CDC/NCIRD)
5:25 PM - Public Comment		
5:40 PM - Adjourn		

AGENDA ITEM	PURPOSE	PRESIDER / PRESENTER(S)
Thursday, June 21, 2012		
8:00 AM - Unfinished Business		Dr. Carol Baker (ACIP Chair)
8:15AM - Agency Updates CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NVPO, NIH		CDC and <i>Ex Officio</i> members
8:30 AM - IOM Vaccine Committee Report Identifying and prioritizing new preventive vaccines for development	Information & Discussion	Dr. Guruprasad Madhavan, Dr. Tracy Lieu (IOM Committee on Identifying and Prioritizing New Vaccines for Development)
9:00 AM - Adult Immunization Introduction Non-influenza vaccination rates among US adults Plans for expanding vaccine coverage tracking for US adults using BRFS Report on first National Adult Immunization Summit	Information & Discussion	Ms. Kristen Ehresmann (ACIP, WG Chair) Dr. Walter Williams (CDC/NCIRD) Dr. Walter Williams (CDC/NCIRD) Dr. Carolyn Bridges (CDC/NCIRD)
9:30 AM - Human Papillomavirus (HPV) Vaccines Introduction IIS sentinel site data: uptake of HPV vaccine in the US HPV vaccine update	Information & Discussion	Dr. Joseph Bocchini (ACIP, WG Chair) Dr. Karen Cullen (CDC/NCIRD) Dr. Lauri Markowitz (CDC/NCHSTP)
10:30 AM - Break		
11:00 AM - Anthrax Vaccine Adsorbed (AVA) Considerations for AVA post-exposure prioritization	Information	Dr. Nancy Messonnier (CDC/NCIRD) Dr. Raymond Strikas (CDC/NCIRD)
11:30 AM - Measles, Mumps, Rubella (MMR) Vaccine Introduction Epidemiology of rubella and congenital rubella syndrome (CRS) in the United States Post exposure prophylaxis for measles with immune globulin Review of policy considerations pertaining to MMR vaccine	Information & Discussion	Dr. Jon Temte (ACIP, WG Chair) Dr. Huong McLean (CDC/NCIRD) Dr. Mark Papania (CDC/NCIRD) Dr. Huong McLean (CDC/NCIRD)
12:45 PM - Public Comment		
1:00 PM - Adjourn		

Acronyms

CMS	Centers for Medicare and Medicaid Services
DoD	Department of Defense
DVA	Department of Veterans Affairs
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
I H S	Indian Health Service
IIS	Immunization Information Systems (Immunization Registries)
IOM	Institute of Medicine
NCCDPHP	National Center for Chronic Disease Prevention and Health Promotion
NCEZID	National Center for Emerging and Zoonotic Infectious Diseases
NCHSTP	National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
NCIRD	National Center for Immunization and Respiratory Diseases
NIH	National Institutes of Health
NVPO	National Vaccine Program Office
PCV13	13-valent Pneumococcal Conjugate Vaccine
PPSV23	23-valent Pneumococcal Polysaccharide Vaccine
SAGE	Strategic Advisory Group of Experts (WHO)
TBD	To be determined
Tdap	Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine
WG	Work Group
WHO	World Health Organization